BioNTech seeks more data on Covid variant - RTHK
A A A
Temperature Humidity
News Archive Can search within past 12 months

BioNTech seeks more data on Covid variant

2021-11-26 HKT 22:42
Share this story facebook
  • BioNTech says it would be able to ship new versions of its Covid vaccine within 100 days. File image: Shutterstock
    BioNTech says it would be able to ship new versions of its Covid vaccine within 100 days. File image: Shutterstock
BioNTech, the inventor of Hong Kong's most widely used Covid-19 vaccine, said it expects more data on a worrying new coronavirus variant detected in South Africa within two weeks to help determine whether its shot would have to be reworked.

"We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529," the biotech firm said in a statement when asked to comment.

"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," it added.

Escape variants are those that elude the targeted immune response brought about by vaccination. Should it be necessary, BioNTech and its international partner Pfizer would be able to redesign their shot within 6 weeks and ship initial batches within 100 days, BioNTech added.

BioNTech shares gained 7 percent, while Pfizer stock was up more than 5 percent in pre-market trading. BioNTech vaccines in Hong Kong are supplied from Europe in a partnership with Fosun Pharma.

Global authorities reacted with alarm on Friday to the new variant, with the EU and Britain among those tightening border controls as scientists sought to find out if the mutation was vaccine-resistant.

Pfizer and BioNTech have already created versions of their established mRNA-based vaccine – based on the original virus found in Wuhan – to target the so-called Alpha and Delta variants, with clinical trials ongoing.

While not meant to yield commercial products, the exercise is carried out to establish a routine with regulators that will help speed up any future vaccine relaunch. (Reuters, additional reporting by RTHK)